Head to head
Henry Meds vs Willow
Both are real, operating US telehealth companies. What separates them is what they supply, what they charge for it, and what regulators have published about each — all of it below, linked to the primary documents.
- Henry Meds
- Compounded
$179/mo - Willow
- Compounded
$299/mo - Henry Meds on file
- 1
- Willow on file
- 3
Side by side
What each one publishes about itself
Every figure here is the provider’s own advertised number, not an estimate. A dash means the company does not publish it.
| Henry Meds | Willow | |
|---|---|---|
| Supplies | Compounded only | Compounded only |
| Advertised from | $179/mo | $299/mo |
| First month | — | — |
| Medication in the price | Included | Included |
| Insurance | Cash pay | Cash pay |
| Intake | Async | Async |
| On the record | 1 action | 3 actions |
The difference that actually matters
Supplies compounded semaglutide or tirzepatide — medication prepared by a compounding pharmacy, not an FDA-approved product. Cheaper, legal, and the category the FDA has been issuing warning letters about.
What is on Henry Meds’s record
2025-04
Eli Lilly sued Adonis Health, Inc. d/b/a Henry Meds in the Northern District of California on 23 April 2025 (No. 4:25-cv-03536) over its marketing of compounded tirzepatide against Mounjaro and Zepbound. In September 2025 the court dismissed Lilly's safety and efficacy claims and allowed its personalisation claims to proceed.
What is on Willow’s record
2025-12
The National Advertising Division, on a challenge by Novo Nordisk, recommended on 4 December 2025 that Willow Health Services discontinue or modify health claims for its compounded semaglutide products. Willow declined to provide a compliance statement, and NAD referred the matter to regulatory authorities and to the platforms carrying the advertising.
2026-07
Reopened NAD matter closed after Willow Health Services voluntarily discontinued claims that its compounded semaglutide was proven to support weight loss, delivered results comparable to FDA-approved semaglutide, and produced effective weight loss without diet or exercise.
2026-02
Eli Lilly sued Willow Health Services, Inc. in the Central District of California on 23 April 2025 (No. 2:25-cv-03570) over compounded tirzepatide. The case was dismissed with prejudice on 3 February 2026 for failure to establish Lanham Act standing — the court held the prescribing physician, not Willow's advertising, was the proximate cause of any lost sales — with no ruling on whether the marketing was misleading. Lilly has appealed to the Ninth Circuit (No. 26-1317).
Go direct
Both companies, and what we earn from each
We do not recommend one over the other. Where a link pays us, it says so here and on the provider’s own page.
Henry Meds
Compounded only, from $179 a month. 1 action on record, each linked on its page. The link below earns us nothing.
Willow
Compounded only, from $299 a month. 3 actions on record, each linked on its page. The link below is an affiliate link and pays us a commission; it changed nothing above.
Straight answers
Henry Meds vs Willow, in short
- Is Henry Meds or Willow cheaper?
- Henry Meds advertises the lower starting price — $179 a month against $299, roughly 1.7× the difference. Whether that is the cheaper purchase depends on what each figure covers: Henry Meds includes medication, and Willow includes it.
- What is the difference between Henry Meds and Willow?
- Both supply the same category — compounded medication only — so the differences are price, how the consultation works, and what each one has on its regulatory record.
- Which one has more regulatory actions on record?
- Willow, with 3 sourced actions against 1 action for Henry Meds. Every one is linked to its primary document on the provider's own page. A larger file is not automatically a worse company — read what the documents actually say.
Other comparisons: Hims vs Henry Meds · Henry Meds vs MEDVi · Henry Meds vs Mochi Health · Henry Meds vs Amble Health · Henry Meds vs TrimRx · Henry Meds vs Curex